Fewer than a tenth of people eligible to benefit from weight-loss injections such as Wegovy have access to them, states the WHO as it issues its first guidance on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for increased and just availability to this class of drugs.
According to projections, over two billion are projected to be living with obesity by 2030 without intervention.
"The new guidelines recognises that excess weight is a lifelong illness that can be addressed with comprehensive and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are significant barriers to broad access to the injections that can aid individuals in losing substantial body mass, notes the organization.
Even in the present most favorable scenario, the production of GLP-1 therapies would only suffice for around 100 million people – less than 10% of eligible patients, according to the health organization.
The advice urges nations and manufacturers to expand access, by strategies like voluntary licensing.
The intellectual property rights on a key compound – the main component of the drug Wegovy – is scheduled to end in several countries in 2026.
The injections imitate a natural hormone to delay gastric emptying, curb appetite and enhance the sense of being full so users eat less.
Individuals usually see weight reduction after several weeks of starting on the regular doses.
Studies suggests patients may see weight return within a year of stopping the medication, because their typical appetite resume.
Being above a healthy weight elevates your risk for contracting medical conditions, including diabetes, heart disease, stroke, and specific cancers.
Excess weight impacts people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, as per the WHO.
A seasoned gambling analyst with over a decade of experience in casino trends and game strategies.
Erin Black
Erin Black
Erin Black
Erin Black
Erin Black